Skip to main content
SpringerLink
Log in

Effect of Antiepileptic Drugs on Bodyweight

Overview and Clinical Implications for the Treatment of Epilepsy

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

The potential of specific antiepileptic drugs (AEDs) to cause clinically significant changes in bodyweight is a key consideration in the management of epilepsy; changes in weight can pose health hazards, impair body image and self-esteem, and lead to noncompliance with therapy. This article reviews the data regarding the effects of conventional and newer AEDs on weight and discusses the clinical implications of these effects for the management of patients with epilepsy. The data demonstrate that AEDs can differ substantially in their effects on weight. Some, such as valproate and carbamazepine, increase weight; others, such as topiramate and felbamate, decrease it. Still others, such as lamotrigine, levetiracetam and phenytoin, are weight neutral.

Because most data regarding the effects of AEDs on weight are circumstantial, the incidence, magnitude and determinants of weight changes with AEDs remain poorly elucidated. Furthermore, little is known about the mechanisms of AED-induced changes in weight.

The importance of effects on weight in selecting an AED depends largely upon the individual patient’s needs and the risks and benefits of therapy for that patient. The most appropriate therapeutic choice is a weight-neutral medication unless circumstances dictate otherwise.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Asconape JJ. Some common issues in the use of antiepileptic drugs. Semin Neurol 2002; 22: 27–39

    Article  PubMed  Google Scholar 

  2. Foster D. Gain and loss in weight. In: Fauci S, editor. Harrison’s principles of internal medicine. 14th ed. New York: McGraw Hill, 1998

    Google Scholar 

  3. Vanina Y, Podolskaya A, Sedky K, et al. Body weight changes associated with psychopharmacology. Psychiatr Serv 2002; 53: 842–7

    Article  PubMed  Google Scholar 

  4. Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf 2001; 24: 969–78

    Article  PubMed  CAS  Google Scholar 

  5. McGinnis J, Foege W. Actual causes of death in the United States. JAMA 1993; 270: 2207–12

    Article  PubMed  CAS  Google Scholar 

  6. Burton BR, Foster WR, Hirsch J, et al. Health implications of obesity: NIH consensus development conference. Int J Obes Relat Metab Disord 1985; 9: 155–69

    CAS  Google Scholar 

  7. Schmidt D. Adverse effects of valproate. Epilepsia 1984; 25Suppl. 1: S44–9

    Article  PubMed  Google Scholar 

  8. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci 1997; 24: 240–4

    PubMed  CAS  Google Scholar 

  9. Easter D, O’Bryan-Tear CG, Verity C. Weight gain with valproate or carbamazepine: a reappraisal. Seizure 1997; 6: 121–5

    Article  PubMed  CAS  Google Scholar 

  10. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. BMJ 1981; 283: 577–81

    Article  PubMed  CAS  Google Scholar 

  11. Dinesen H, Gram L, Andersen T, et al. Weight gain during treatment with valproate. Acta Neurol Scand 1984; 69: 65–9

    Article  Google Scholar 

  12. Isojärvi JIT, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996; 39: 579–84

    Article  PubMed  Google Scholar 

  13. Novak GP, Maytal J, Alshansky A, et al. Risk of excessive weight gain in epileptic children treated with valproate. J Child Neurol 1999; 14: 490–5

    Article  PubMed  CAS  Google Scholar 

  14. Verrotti A, Basciani F, Morresi S, et al. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999; 53: 230–2

    Article  PubMed  CAS  Google Scholar 

  15. Demir E, Aysun S. Weight gain associated with valproate in childhood. Pediatr Neurol 2000; 22: 361–4

    Article  PubMed  CAS  Google Scholar 

  16. Vainionpaa LK, Rättyä J, Knip M, et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999; 45: 444–50

    Article  PubMed  CAS  Google Scholar 

  17. Isojärvi JIT, Tapanainen JS. Valproate, hyperandrogenism, and polycystic ovaries: a report of 3 cases. Arch Neurol 2000; 57: 1064–8

    Article  PubMed  Google Scholar 

  18. Isojärvi JIT, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43: 446–51

    Article  PubMed  Google Scholar 

  19. Luef G, Abraham I, Haslinger M, et al. Polycystic ovaries, obesity and insulin resistance in women with epilepsy: a comparative study of carbamazepine and valproic acid in 105 women. J Neurol 2002; 249: 835–41

    Article  PubMed  CAS  Google Scholar 

  20. Pijl H, Meinders AE. Bodyweight changes as an adverse effect of drug treatment: mechanisms and management. Drug Saf 1996; 14: 329–42

    Article  PubMed  CAS  Google Scholar 

  21. Mattson TH, Cramer JA, Collins JF, et al. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992; 327: 765–71

    Article  PubMed  CAS  Google Scholar 

  22. Richens A, Davidson DLW, Cartlidge NEF, et al. A multicenter comparative trial of sodium valproate and carbamazepine in adult-onset epilepsy. J Neurol Neurosurg Psychiatry 1994; 57: 682–7

    Article  PubMed  CAS  Google Scholar 

  23. Verity CM, Hosking G, Easter DJ, et al. A multicenter comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. Dev Med Child Neurol 1995; 37: 97–108

    Article  PubMed  CAS  Google Scholar 

  24. Aston MG, Ball SG, Thomas LH, et al. Water intoxication associated with carbamazepine treatment. BMJ 1977; 1: 1134–5

    Article  Google Scholar 

  25. Lampl Y, Eshel Y, Rapaport A, et al. Weight gain, increased appetite, and excessive food intake induced by carbamazepine. Clin Neuropharmacol 1991; 14: 251–5

    Article  PubMed  CAS  Google Scholar 

  26. Kimura T, Matsui K, Sato T, et al. Mechanism of carbamazepine-induced antidiuresis: evidence for release of antidiuretic hormone and impaired excretion of a water load. J Clin Endocrinol Metab 1974; 38: 356–62

    Article  PubMed  CAS  Google Scholar 

  27. Meinders AE, Cejka V, Robertson G. The antidiuretic action of carbamazepine in man. Clin Sci Mol Med 1974; 47: 289–99

    PubMed  CAS  Google Scholar 

  28. Sorensen PS, Hammer M. Effects of long-term carbamazepine treatment on water metabolism and plasma vasopressin concentration. EurJ Clin Pharmacol 1984; 26: 719–22

    Article  Google Scholar 

  29. Krause KH, Rascher W, Berlit P. Plasma arginine vasopressin concentrations in epileptics under monotherapy. J Neurol 1983; 230: 193–6

    Article  PubMed  CAS  Google Scholar 

  30. Garofalo EA, Hartman T, Hayes A, et al. Weight changes during a gabapentin 26-week monotherapy trial [abstract 6.34]. Epilepsia 1996; 37 Suppl. 5: 160

    Google Scholar 

  31. King JA, Bayles RL. Weight gain during add-on therapy using gabapentin [abstract 3.60]. Epilepsia 1995; 36 Suppl. 4: 72

    Google Scholar 

  32. Asconape J, Collins T. Weight gain associated with the use of gabapentin [abstract 3.58]. Epilepsia 1995; 36 Suppl. 4: 72

    Google Scholar 

  33. Gidal BE, Maly MM, Nemire RE, et al. Weight gain and gabapentin therapy [letter]. Ann Pharmacother 1995; 29: 1048

    PubMed  CAS  Google Scholar 

  34. DeToledo JC, Toledo C, DeCerce J, et al. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit 1997; 19: 394–6

    Article  PubMed  CAS  Google Scholar 

  35. Cahill WT, Mozahem K, Privitera MD. Weight changes with the use of gabapentin [abstract 2.090]. Epilepsia 1998; 39 Suppl. 6: 54

    Google Scholar 

  36. Leibowitz SF. Neurochemical-neuroendocrine systems in the brain controlling macronutrient intake and metabolism. Trends Neurosci 1992; 15: 491–7

    Article  PubMed  CAS  Google Scholar 

  37. Remy C, Beaumont D. Efficacy and safety of vigabatrin in the long-term treatment of the refractory epilepsy. Br J Clin Pharmacol 1989; 27Suppl. 1: S125–9

    Article  Google Scholar 

  38. Tartara A, Manni R, Galimberti CA, et al. Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. Acta Neurol Scand 1992; 96: 247–51

    Article  Google Scholar 

  39. Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicenter randomised double-blind study. Lancet 1999; 354: 13–9

    Article  PubMed  CAS  Google Scholar 

  40. Guberman A, Bruni J. Long-term open multicenter, add-on trial of vigabatrin in adult resistant partial epilepsy. Seizure 2000; 9: 112–8

    Article  PubMed  CAS  Google Scholar 

  41. Uldall P, Alving J, Gram L, et al. Vigabatrin in childhoodepilepsy: a 5-year follow-up study. Neuropediatrics 1995; 26:253–6

    Article  PubMed  CAS  Google Scholar 

  42. Guberman A. Vigabatrin. Can J Neurol Sci 1996; 23: S13–7

    PubMed  CAS  Google Scholar 

  43. Pellock JM, Morton LD. Treatment of epilepsy in the multi-handicapped. Ment Retard Dev Disabil Res Rev 2000; 6: 309–23

    Article  PubMed  CAS  Google Scholar 

  44. Coppola G, Caliendo G, Terracciano MM, et al. Topiramate in refractory partial-onset seizures in children, adolescents and young adults: a multicentric open trial. Epilepsy Res 2001; 43: 255–60

    Article  PubMed  CAS  Google Scholar 

  45. Levisohn PM. Safety and tolerability of topiramate in children. J Child Neurol 2000; 15Suppl. 1: S22–6

    Article  PubMed  Google Scholar 

  46. Stephen LJ, Sills GJ, Brodie MJ. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia 2000; 41: 977–80

    Article  PubMed  CAS  Google Scholar 

  47. Mohamed K, Appleton R, Rosenbloom L. Efficacy and tolerability of topiramate in childhood and adolescent epilepsy: a clinical experience. Seizures 2000; 9: 137–41

    Article  CAS  Google Scholar 

  48. Ben-Menachem E, Smith U, Hellstrom K, et al. Prospective study on metabolism and weight changes in patients with epilepsy treated with topiramate [abstract]. Epilepsia 2000; 41Suppl. 7: 222

    Google Scholar 

  49. Teter CJ, Early JJ, Gibbs CM. Treatment of affective disorder and obesity with topiramate. Ann Pharmacother 2000; 34: 1262–4

    Article  PubMed  CAS  Google Scholar 

  50. Erfurth A, Kuhn G. Topiramate monotherapy in the maintenance treatment of bipolar I disorder: effects on mood, weight and serum lipids. Neuropsychobiology 2000; 42 Suppl. 1: 50–1

    Article  Google Scholar 

  51. Lessig MC, Shapira NA, Murphy TK. Topiramate for reversing atypical antipsychotic weight gain [letter]. J Am Acad Child Adolesc Psychiatry 2001; 40: 1364

    Article  PubMed  CAS  Google Scholar 

  52. Chengappa KNR, Levine J, Rathore D, et al. Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur Psychiatry 2001; 16: 186–90

    Article  Google Scholar 

  53. Shuaib A, Ahmad F, Kochanski P, et al. Efficacy of topiramate in prophylaxis of frequent severe migraines or chronic daily headaches: experience with 70 patients over 18 months [abstract]. Cephalalgia 2000; 20: 423

    Google Scholar 

  54. Von Seggern RL, Mannix LK, Adelman JU. Efficacy of topiramate in prophylactic treatment of migraines in patients refractory to preventative intervention: a retrospective chart review in a tertiary clinic [abstract]. Cephalalgia 2000; 20: 423

    Google Scholar 

  55. Wilson MC. Efficacy of topiramate in the prophylactic treatment of intractable chronic migraine: retrospective chart review [abstract]. Cephalalgia 2000; 20: 301

    Google Scholar 

  56. Edwards KR, Glantz MJ, Button J, et al. Efficacy and safety of topiramate in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study [abstract]. Neurology 2000; 54Suppl. 3: A81

    Google Scholar 

  57. Brown RO, Orr CD, Hanna DL, et al. Topiramate and weight loss in patients with neurodevelopmental disabilities. Pharmacotherapy 2002; 22: 831–5

    Article  PubMed  CAS  Google Scholar 

  58. Richard D, Ferland J, Lalonde J, et al. Influence of topiramate in the regulation of energy balance. Nutrition 2000; 16: 961–6

    Article  PubMed  CAS  Google Scholar 

  59. Carmant L, Holmes GL, Sawyer S, et al. Efficacy of felbamate in therapy for partial epilepsy in children. J Pediatr 1994; 125: 481–6

    Article  PubMed  CAS  Google Scholar 

  60. Graves NM. Felbamate. Ann Pharmacother 1993; 27: 1073–81

    PubMed  CAS  Google Scholar 

  61. Cilio MR, Kartashov AI, Vigevano F. The long-term use of felbamate in children with severe refractory epilepsy. Epilepsy Res 2001; 47: 1–7

    Article  PubMed  CAS  Google Scholar 

  62. Felbatol (felbamate) package insert. Cranbury (NJ): Wallace Laboratories, 1999

  63. Bergen DC, Ristanovic RK, Waicosky K, et al. Weight loss in patients taking felbamate. Clin Neuropharmacol 1995; 18: 23–7

    Article  PubMed  CAS  Google Scholar 

  64. Faught E, Ayala R, Montouris GG, et al. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001; 57: 1774–9

    Article  PubMed  CAS  Google Scholar 

  65. Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration. Oxford: Oxford Update Software, 2002: CD001416

    Google Scholar 

  66. Thilothammal N, Banu K, Ratnam RS. Comparison of phenobarbitone, phenytoin, with sodium valproate: a randomized, double-blind study. Indian Pediatr 1996; 33: 549–55

    PubMed  CAS  Google Scholar 

  67. Finkel MJ. Phenytoin revisited. Clin Ther 1984; 6: 577–91

    PubMed  CAS  Google Scholar 

  68. Hayes G, Kootsikas ME. Reassessing the lower end of the phenytoin therapeutic range: a review of the literature. Ann Pharmacother 1993; 27: 1389–92

    PubMed  CAS  Google Scholar 

  69. Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001; 56: 172–7

    Article  PubMed  CAS  Google Scholar 

  70. Devinsky O, Vuong A, Hammer A, et al. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology 2000; 54: 973–5

    Article  PubMed  CAS  Google Scholar 

  71. Ueberall MA. Normal growth during lamotrigine monotherapy in pediatric epilepsy patients: a prospective evaluation of 103 children and adolescents. Epilepsy Res 2001; 46: 63–7

    Article  PubMed  CAS  Google Scholar 

  72. Gidal B, Sheth R, Maganti R, et al. Levetiracetam weight change during placebo-controlled clinical trials [abstract]. Epilepsia 2001; 42Suppl. 7: 157

    Google Scholar 

  73. Loiseau P. Review of controlled trials of Gabitril: a clinician’s viewpoint. Epilepsia 1999; 40Suppl. 9: S14–9

    Article  PubMed  CAS  Google Scholar 

  74. Hogan RE, Bertrand ME, Deaton RL, et al. Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine, and phenytoin. Epilepsy Res 2000; 41: 23–8

    Article  PubMed  CAS  Google Scholar 

  75. Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs 2001; 15(2): 137–63

    Article  PubMed  CAS  Google Scholar 

  76. Rattya J, Vainionpaa L, Knip M, et al. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999; 103: 588–93

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The author thanks Jane Saiers, PhD for assistance with writing this review. Dr Saiers’ work was supported by GlaxoSmithKline, maker of lamotrigine.

Dr Biton has received clinical research grants from Abbott, Élan, GlaxoSmithKline, Hoechst Marion Roussel, Novartis, Ortho McNeil, RWJ Pharmaceutical Research Institute, Pfizer and UCB Pharma. Dr Biton is on the Speaker’s Bureau for Ortho McNeil, GlaxoSmithKline, Novartis, Élan and UCB Pharma. Dr Biton did not receive funding for the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Arkansas Epilepsy Program, 2 Lile Court, Suite 100, Little Rock, Arkansas, 72205, USA

    Victor Biton

Authors
  1. Victor Biton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Victor Biton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Biton, V. Effect of Antiepileptic Drugs on Bodyweight. CNS Drugs 17, 781–791 (2003). https://doi.org/10.2165/00023210-200317110-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200317110-00002

Keywords

Search

Navigation